查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1565654

艱難梭菌感染治療市場，按類型、給藥途徑、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Clostridium Difficile Infection Treatment Market, By Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年，艱難梭菌感染治療市場規模為8.969億美元，2024年至2032年複合年成長率為7.90%。

艱難梭菌感染治療市場-市場動態

院內感染發病率上升推動了對艱難梭菌感染治療解決方案的需求

院內感染 (HAIs) 盛行率的不斷上升，加劇了對艱難梭菌感染有效治療的需求。根據美國疾病管制與預防中心 (CDC) 的數據，醫院感染每天影響約三分之一的醫院患者，其中艱難梭菌是最常見的罪魁禍首之一。 2020 年，CDC 報告稱，光是在美國，艱難梭菌就導致近 223,900 例住院患者感染，造成 12,800 多人死亡。醫療機構為減少醫院感染所做的努力以及嚴格的感染控制措施正在推動更先進、更有針對性的治療方法的採用。由於人們對抗生素抗藥性的持續擔憂，作為對抗這些感染的更廣泛策略的一部分，糞便微生物移植 (FMT) 等替代療法的發展勢頭強勁。

艱難梭菌感染治療市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 7.90% 左右的複合年成長率成長

根據類型細分，預計抗生素將在 2023 年顯示最大的市場佔有率

根據給藥途徑細分，2023年口服是領先類型

按地區分類，北美是 2023 年的主要收入來源

艱難梭菌感染治療市場-細分分析：

全球艱難梭菌感染治療市場根據類型、給藥途徑、最終用戶和地區進行細分。

市場依類型分為四大類：抗生素、益生菌、糞便微生物移植（FMT）和單株抗體。抗生素因其廣泛使用而在艱難梭菌感染治療市場中佔據主導地位，其次是糞便微生物移植（FMT）作為替代療法的發展勢頭。單株抗體不斷湧現，而益生菌作為支持性治療越來越受到關注。

根據給藥途徑，市場分為三類：口服、靜脈注射和直腸給藥。由於簡單且患者依從性良好，口服給藥是艱難梭菌治療中最常見的，其次是靜脈給藥，用於治療嚴重病例。直腸給藥較不常見，但用於糞便微生物移植 (FMT) 等標靶治療。

艱難梭菌感染治療市場 - 地理洞察

艱難梭菌感染治療市場顯示出顯著的地區差異，其中北美由於高感染率和強大的醫療基礎設施而處於領先地位。 CDC 估計，艱難梭菌每年在美國造成近 12,800 人死亡，使其成為公共衛生措施的重點對象。歐洲緊隨其後，歐洲疾病預防和控制中心（ECDC）實施了嚴格的感染控制措施，包括強制報告醫院感染，這刺激了市場成長。亞太地區的意識不斷提高，診斷能力不斷提高，特別是在日本和中國等國家。 2021年，日本厚生省發起了減少抗菌藥物抗藥性的舉措，直接影響了對CDI治療的需求。拉丁美洲以及中東和非洲地區雖然採用先進療法的速度較慢，但在感染率上升和加強醫療保健系統的努力的推動下，醫療保健投資不斷增加。這些地區正在逐步改善獲得創新治療的機會，創造未來的市場潛力。

艱難梭菌感染治療市場-競爭格局：

艱難梭菌感染治療市場競爭激烈，主要參與者專注於合作夥伴關係、收購和藥物創新等策略性措施。默克公司和輝凌製藥等領先公司處於市場的前沿。默克的 DIFICID(R) (fidaxomicin) 仍然是領先的治療選擇，2022 年，該公司宣布與生物醫學高級研究與發展局 (BARDA) 建立合作夥伴關係，探索下一代療法。 Ferring Pharmaceuticals 因收購Rebiotix, Inc. 而成為頭條新聞，加速了其基於微生物組的療法的開發，其中包括FDA 批准的REBYOTA(R)，這是一種針對CDI 的開創性糞便微生物移植(FMT) 療法。輝瑞(Pfizer) 也正在取得長足進步，正在研發一種艱難梭菌候選疫苗，該疫苗將於2021 年進入後期臨床試驗。嚴重的全球艱難梭菌感染負擔，為未來的成長和創新而努力。

最新進展：

2023 年 4 月，Seres Therapeutics 和雀巢健康科學宣布 FDA 批准 VOWST，這是第一個基於口服微生物群的療法，用於預防成人抗菌治療後復發性艱難梭菌感染。該產品預計將於六月上市。

2024 年 5 月，Acurx Pharmaceuticals 宣布成功召開了 FDA 伊貝札波爾他 2 期結束會議，確認了治療艱難梭菌感染的國際 3 期試驗計畫。 FDA 批准了試驗設計和終點，為提交新藥申請鋪平了道路。

目錄

第1章：艱難梭菌感染治療市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 艱難梭菌感染治療市場片段（按類型）
    • 依給藥途徑分類的艱難梭菌感染治療市場片段
    • 最終使用者的艱難梭菌感染治療市場片段
    • 艱難梭菌感染治療市場片段（依國家/地區）
    • 艱難梭菌感染治療市場片段（按地區）
  • 競爭洞察

第 3 章：艱難梭菌感染治療主要市場趨勢

  • 艱難梭菌感染治療市場促進因素
    • 市場促進因素的影響分析
  • 艱難梭菌感染治療市場限制
    • 市場限制影響分析
  • 艱難梭菌感染治療市場機會
  • 艱難梭菌感染治療市場未來趨勢

第 4 章：艱難梭菌感染治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：艱難梭菌感染治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：艱難梭菌感染治療市場格局

  • 2023 年艱難梭菌感染治療市佔率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：艱難梭菌感染治療市場 - 按類型

  • 概述
    • 按類型分類的細分市場佔有率分析
    • 抗生素
    • 益生菌
    • 糞便微生物移植（FMT）
    • 單株抗體

第 8 章：艱難梭菌感染治療市場 - 依給藥途徑

  • 概述
    • 按給藥途徑分類的細分市場佔有率分析
    • 口服
    • 靜脈
    • 直腸

第 9 章：艱難梭菌感染治療市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院
    • 診所
    • 長期照護設施
    • 家庭護理設置

第 10 章：艱難梭菌感染治療市場 - 依地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美艱難梭菌感染治療主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按類型）
    • 北美市場規模與預測（按管理途徑）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲艱難梭菌感染治療主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模與預測（按類型）
    • 歐洲市場規模與預測（按管理途徑）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區艱難梭菌感染治療主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（按類型）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲艱難梭菌感染治療主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按類型）
    • 拉丁美洲市場規模與預測（按管理途徑）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲艱難梭菌感染治療主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按類型）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模和預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 艱難梭菌感染治療產業

  • 競爭儀表板
  • 公司簡介
    • Acurx Pharmaceuticals, Inc.
    • Da Volterra
    • Ferring Pharmaceuticals Inc.
    • Finch Therapeutics Group, Inc.
    • Immuron Ltd.
    • Johnson & Johnson Services, Inc.
    • Maat Pharma SA
    • Merck & Co., Inc.
    • Microbiotica Ltd.
    • Pfizer Inc.
    • Prokaryotics Inc.
    • Rebiotix Inc. (a Ferring company)
    • Sanofi SA
    • Seres Therapeutics, Inc.
    • Summit Therapeutics plc
    • Vedanta Biosciences, Inc.
    • Others

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV3813

REPORT HIGHLIGHT

Clostridium Difficile Infection Treatment Market size was valued at USD 896.90 Million in 2023, expanding at a CAGR of 7.90% from 2024 to 2032.

The Clostridium Difficile Infection (CDI) Treatment Market focuses on therapeutic solutions to combat infections caused by the Clostridium difficile bacterium, which leads to severe diarrhea and inflammation of the colon. The rising incidence of hospital-acquired infections, coupled with the increasing use of broad-spectrum antibiotics, has fueled the demand for effective CDI treatments. Innovative drug developments, such as microbiome therapeutics and monoclonal antibodies, are reshaping the market landscape. Regulatory challenges, particularly in drug approval pathways, act as barriers to market growth. However, with over 450,000 cases of CDI reported annually in the U.S. alone, there is significant opportunity for the development of novel treatment solutions. In addition, the growing awareness of antimicrobial resistance highlights the need for safer and more targeted treatment options, opening avenues for companies to invest in next-generation therapies.

Clostridium Difficile Infection Treatment Market- Market Dynamics

Rising Incidence of Hospital-Acquired Infections Boosts Demand for Clostridium Difficile Infection Treatment Solutions

The increasing prevalence of hospital-acquired infections (HAIs) has intensified the need for effective treatments for Clostridium Difficile infections. According to the Centers for Disease Control and Prevention (CDC), HAIs affect approximately 1 in 31 hospital patients daily, with Clostridium Difficile being one of the most common culprits. In 2020, the CDC reported that C. difficile caused nearly 223,900 infections in hospitalized patients in the U.S. alone, leading to over 12,800 deaths. Efforts by healthcare institutions to reduce HAIs, along with stringent infection control measures, are driving the adoption of more advanced and targeted treatments. With ongoing concerns about antibiotic resistance, the development of alternative therapies, such as fecal microbiota transplants (FMT), has gained momentum as part of a broader strategy to combat these infections.

Clostridium Difficile Infection Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.90% over the forecast period (2024-2032)

Based on Type segmentation, Antibiotics was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Clostridium Difficile Infection Treatment Market- Segmentation Analysis:

The Global Clostridium Difficile Infection Treatment Market is segmented on the basis of Type, Route of Administration, End-User, and Region.

The market is divided into four categories based on Type: Antibiotics, Probiotics, Fecal Microbiota Transplantation (FMT), and Monoclonal Antibodies. Antibiotics dominate the Clostridium Difficile Infection Treatment Market due to their widespread use, followed by Fecal Microbiota Transplantation (FMT) gaining momentum as an alternative therapy. Monoclonal antibodies are emerging, while probiotics are seeing increasing attention as supportive treatments.

The market is divided into three categories based on the Route of Administration: Oral, Intravenous, and Rectal. Oral administration is the most common for Clostridium difficile treatments due to ease and patient compliance, followed by intravenous administration, which is used for severe cases. Rectal administration is less common but utilized for targeted therapies like Fecal Microbiota Transplantation (FMT).

Clostridium Difficile Infection Treatment Market- Geographical Insights

The Clostridium Difficile Infection Treatment Market shows significant regional variation, with North America leading due to high infection rates and robust healthcare infrastructure. The CDC estimates that C. difficile causes nearly 12,800 deaths annually in the U.S., making it a critical focus for public health initiatives. Europe follows closely, where the European Centre for Disease Prevention and Control (ECDC) has implemented strict infection control measures, including mandatory reporting of HAIs, which has spurred market growth. The Asia-Pacific region is witnessing rising awareness and improved diagnostic capabilities, particularly in countries like Japan and China. In 2021, Japan's Ministry of Health launched initiatives to reduce antimicrobial resistance, directly impacting the demand for CDI treatments. Latin America and the Middle East & Africa regions, though slower to adopt advanced therapies, are seeing increasing investments in healthcare, driven by rising infection rates and efforts to strengthen healthcare systems. These regions are gradually improving access to innovative treatments, creating future market potential.

Clostridium Difficile Infection Treatment Market- Competitive Landscape:

The Clostridium Difficile Infection Treatment Market is highly competitive, with key players focusing on strategic initiatives such as partnerships, acquisitions, and drug innovation. Leading companies like Merck & Co., Inc. and Ferring Pharmaceuticals are at the forefront of the market. Merck's DIFICID(R) (fidaxomicin) remains a leading treatment option, and in 2022, the company announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to explore next-generation therapies. Ferring Pharmaceuticals made headlines with its acquisition of Rebiotix, Inc., accelerating its development of microbiome-based therapies, including the FDA-approved REBYOTA(R), a pioneering fecal microbiota transplant (FMT) therapy for CDI. Pfizer, too, is making strides, working on a C. difficile vaccine candidate that entered late-stage clinical trials in 2021. These strategic moves demonstrate how major players are not only competing but also collaborating to address the growing global burden of CDI, positioning themselves for future growth and innovation.

Recent Developments:

In April 2023, Seres Therapeutics and Nestle Health Science announced FDA approval for VOWST, the first orally administered microbiota-based therapy for preventing recurrent Clostridioides difficile infections in adults after antibacterial treatment. The product is expected to be available in June.

In May 2024, Acurx Pharmaceuticals announced a successful FDA End-of-Phase 2 meeting for ibezapolstat, confirming plans for international Phase 3 trials to treat C. difficile infection. The FDA approved the trial design and endpoints, paving the way for the submission of the New Drug Application.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CLOSTRIDIUM DIFFICILE INFECTION TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Acurx Pharmaceuticals, Inc.
  • Da Volterra
  • Ferring Pharmaceuticals Inc.
  • Finch Therapeutics Group, Inc.
  • Immuron Ltd.
  • Johnson & Johnson Services, Inc.
  • Maat Pharma SA
  • Merck & Co., Inc.
  • Microbiotica Ltd.
  • Pfizer Inc.
  • Prokaryotics Inc.
  • Rebiotix Inc. (a Ferring company)
  • Sanofi S.A.
  • Seres Therapeutics, Inc.
  • Summit Therapeutics plc
  • Vedanta Biosciences, Inc.
  • Others

GLOBAL CLOSTRIDIUM DIFFICILE INFECTION TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Antibiotics
  • Probiotics
  • Fecal Microbiota Transplantation (FMT)
  • Monoclonal Antibodies

GLOBAL CLOSTRIDIUM DIFFICILE INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous
  • Rectal

GLOBAL CLOSTRIDIUM DIFFICILE INFECTION TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Long-Term Care Facilities
  • Homecare Settings

GLOBAL CLOSTRIDIUM DIFFICILE INFECTION TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Clostridium Difficile Infection Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Clostridium Difficile Infection Treatment Market Snippet by Type
    • 2.1.2. Clostridium Difficile Infection Treatment Market Snippet by Route of Administration
    • 2.1.3. Clostridium Difficile Infection Treatment Market Snippet by End-User
    • 2.1.4. Clostridium Difficile Infection Treatment Market Snippet by Country
    • 2.1.5. Clostridium Difficile Infection Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Clostridium Difficile Infection Treatment Key Market Trends

  • 3.1. Clostridium Difficile Infection Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Clostridium Difficile Infection Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Clostridium Difficile Infection Treatment Market Opportunities
  • 3.4. Clostridium Difficile Infection Treatment Market Future Trends

4. Clostridium Difficile Infection Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Clostridium Difficile Infection Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Clostridium Difficile Infection Treatment Market Landscape

  • 6.1. Clostridium Difficile Infection Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Clostridium Difficile Infection Treatment Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Antibiotics
    • 7.1.3. Probiotics
    • 7.1.4. Fecal Microbiota Transplantation (FMT)
    • 7.1.5. Monoclonal Antibodies

8. Clostridium Difficile Infection Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Intravenous
    • 8.1.4. Rectal

9. Clostridium Difficile Infection Treatment Market - By End-User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Clinics
    • 9.1.4. Long-Term Care Facilities
    • 9.1.5. Homecare Settings

10. Clostridium Difficile Infection Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Clostridium Difficile Infection Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Clostridium Difficile Infection Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Clostridium Difficile Infection Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Clostridium Difficile Infection Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Clostridium Difficile Infection Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Clostridium Difficile Infection Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Acurx Pharmaceuticals, Inc.
    • 11.2.2. Da Volterra
    • 11.2.3. Ferring Pharmaceuticals Inc.
    • 11.2.4. Finch Therapeutics Group, Inc.
    • 11.2.5. Immuron Ltd.
    • 11.2.6. Johnson & Johnson Services, Inc.
    • 11.2.7. Maat Pharma SA
    • 11.2.8. Merck & Co., Inc.
    • 11.2.9. Microbiotica Ltd.
    • 11.2.10. Pfizer Inc.
    • 11.2.11. Prokaryotics Inc.
    • 11.2.12. Rebiotix Inc. (a Ferring company)
    • 11.2.13. Sanofi S.A.
    • 11.2.14. Seres Therapeutics, Inc.
    • 11.2.15. Summit Therapeutics plc
    • 11.2.16. Vedanta Biosciences, Inc.
    • 11.2.17. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us